Skip Navigation


European Heart Journal Advance Access originally published online on August 1, 2007
European Heart Journal 2007 28(19):2369-2374; doi:10.1093/eurheartj/ehm327
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/19/2369    most recent
ehm327v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dunning, J.
Right arrow Articles by Hunter, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunning, J.
Right arrow Articles by Hunter, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Stentless vs. stented aortic valve bioprostheses: a prospective randomized controlled trial

J. Dunning*, R.J. Graham, J. Thambyrajah, M.J. Stewart, S.W.H. Kendall and S. Hunter

Department of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, TS4 3BW, UK

Received 12 February 2007; revised 13 June 2007; accepted 6 July 2007; online publish-ahead-of-print 1 August 2007.

* Corresponding author. Tel: +44 7801548122; fax: +44 7801548122. E-mail address: joeldunning{at}doctors.org.uk

Aims: We sought to assess the haemodynamic profile of the Freedom stentless aortic valve compared with a stented bioprosthesis in a randomized controlled trial using echocardiography.

Methods and results: Sixty patients (mean age 73 years) undergoing bioprosthetic aortic valve replacement (AVR) were randomized to either Sorin Freedom stentless (n = 31) or Sorin More stented (n = 29) valves. The primary endpoints were left ventricular mass index (LVMI) reduction at 6 and 12-months. We also assessed post-operative effective orifice area index (EOAI), aortic gradient and operative time. There were no significant differences in baseline characteristics. The stentless valve was associated with a lower post-operative gradient [PG 17 (12) vs. 31 (13) mmHg, P < 0.0001] and greater EOAI [1.1 (0.3) vs. 0.8 (0.2) cm2/m2, P < 0.0001]. A highly significant reduction in LVMI occurred by 6 months in both groups, but LVMI was significantly lower in the stentless group [LVMI 119 (39) vs. 135 (30) g/m2, P = 0.05]. However, there was continued regression of left ventricular hypertrophy (LVH) in the stented but not in the stentless group, resulting in no significant difference in LVMI at 12 months [119 (36) vs. 126 (31) g/m2, P = 0.42].

Conclusion: The use of the Sorin Freedom stentless bioprosthesis for AVR results in lower PG and greater EOA when compared with a Sorin More stented valve. This is associated with earlier regression of LVH.

Key Words: Aortic valve replacement • Thoracic surgery • Stentless valve • Mass regression


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.